IL83878A
(en)
*
|
1987-09-13 |
1995-07-31 |
Yeda Res & Dev |
Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
|
US6479632B1
(en)
*
|
1988-09-12 |
2002-11-12 |
Yeda Research And Development Co. Ltd. |
Tumor necrosis factor inhibitory protein and its purification
|
IL98078A0
(en)
*
|
1991-05-07 |
1992-06-21 |
Yeda Res & Dev |
Pharmaceutical compositions comprising an anticytokyne
|
US5512544A
(en)
*
|
1987-09-13 |
1996-04-30 |
Yeda Research And Development Co. Ltd. |
Pharmaceutical compositions comprising an anticytokine
|
US5359037A
(en)
*
|
1988-09-12 |
1994-10-25 |
Yeda Research And Development Co. Ltd. |
Antibodies to TNF binding protein I
|
IL94039A
(en)
*
|
1989-08-06 |
2006-09-05 |
Yeda Res & Dev |
Antibodies to tbp - 1 and their use
|
US6221675B1
(en)
|
1989-04-21 |
2001-04-24 |
Amgen, Inc. |
TNF receptors, TNF binding proteins and DNAs coding for them
|
ATE289350T1
(de)
*
|
1989-04-21 |
2005-03-15 |
Amgen Inc |
Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas
|
JPH03164179A
(ja)
*
|
1989-04-21 |
1991-07-16 |
Boehringer Ingelheim Internatl Gmbh |
Tnfレセプター、tnf結合たん白質およびこれらをコードするdna
|
US7264944B1
(en)
|
1989-04-21 |
2007-09-04 |
Amgen Inc. |
TNF receptors, TNF binding proteins and DNAs coding for them
|
DE3922089A1
(de)
*
|
1989-05-09 |
1990-12-13 |
Basf Ag |
Neue proteine und ihre herstellung
|
CA2017025C
(en)
|
1989-05-18 |
2008-07-22 |
David Wallach |
Tumor necrosis factor binding protein ii, its purification and antibodies thereto
|
IL95031A
(en)
*
|
1989-07-18 |
2007-03-08 |
Amgen Inc |
A method of producing a recombinant human necrotic factor absorber
|
US6143866A
(en)
*
|
1989-07-18 |
2000-11-07 |
Amgen, Inc. |
Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
|
US5998378A
(en)
*
|
1989-08-16 |
1999-12-07 |
Chiron Corporation |
Compositions for the inhibition of TNF hormone formation and uses thereof
|
DK0491878T3
(da)
*
|
1989-08-16 |
1997-06-23 |
Chiron Corp |
Præparater til inhibering af proteinhormondannelse og anvendelser deraf
|
US6586222B1
(en)
|
1989-08-16 |
2003-07-01 |
Chiron Corporation |
Recombinant PR-3 and compositions thereof
|
US5843693A
(en)
*
|
1989-08-16 |
1998-12-01 |
Chiron Corporation |
Assay method for screening for inhibitors of proTNF conversion
|
US5945397A
(en)
*
|
1989-09-05 |
1999-08-31 |
Immunex Corporation |
Purified p75 (type II) tumor necrosis factor receptor polypeptides
|
NZ235148A
(en)
|
1989-09-05 |
1991-12-23 |
Immunex Corp |
Tumour necrosis factor receptor protein and dna sequences
|
CA2065346C
(en)
*
|
1989-09-05 |
2005-03-29 |
Craig A. Smith |
Tumor necrosis factor-.alpha. and-.beta. receptors
|
US5605690A
(en)
*
|
1989-09-05 |
1997-02-25 |
Immunex Corporation |
Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
|
US5395760A
(en)
*
|
1989-09-05 |
1995-03-07 |
Immunex Corporation |
DNA encoding tumor necrosis factor-α and -β receptors
|
DK0417563T3
(da)
*
|
1989-09-12 |
2000-11-06 |
Hoffmann La Roche |
TNF-bindende proteiner
|
US5190750A
(en)
*
|
1990-03-09 |
1993-03-02 |
Asahi Kasei Kogyo Kabushiki Kaisha |
Methods for the treatment of demyelinating disease, uveitis, or graft-versus-host disease using tnf
|
US6552170B1
(en)
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
US20030064480A1
(en)
*
|
1990-06-28 |
2003-04-03 |
Leander Lauffer |
Fusion proteins with immunoglobulin portions, the preparation and use thereof
|
AU8337291A
(en)
*
|
1990-08-06 |
1992-03-02 |
Cetus Corporation |
Methods for the identification of cytokine convertase inhibitors
|
EP0480389A1
(de)
*
|
1990-10-12 |
1992-04-15 |
Hoechst Aktiengesellschaft |
Inhibitoren für die Bildung von Tumor Nekrose Faktor, Verfahren zu deren Herstellung und deren Verwendung
|
GB9022648D0
(en)
*
|
1990-10-18 |
1990-11-28 |
Charing Cross Sunley Research |
Polypeptide and its use
|
DK0567566T4
(da)
*
|
1991-01-18 |
2007-10-22 |
Amgen Inc |
Fremgangsmåder til behandling af tumornekrosefaktor-medierede sygdomme
|
US7192584B2
(en)
|
1991-03-18 |
2007-03-20 |
Centocor, Inc. |
Methods of treating psoriasis with anti-TNF antibodies
|
US5656272A
(en)
*
|
1991-03-18 |
1997-08-12 |
New York University Medical Center |
Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
|
US6284471B1
(en)
|
1991-03-18 |
2001-09-04 |
New York University Medical Center |
Anti-TNFa antibodies and assays employing anti-TNFa antibodies
|
US5919452A
(en)
*
|
1991-03-18 |
1999-07-06 |
New York University |
Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
|
US5698195A
(en)
*
|
1991-03-18 |
1997-12-16 |
New York University Medical Center |
Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
|
US6277969B1
(en)
|
1991-03-18 |
2001-08-21 |
New York University |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
US5582998A
(en)
*
|
1991-06-19 |
1996-12-10 |
Boehringer Ingelheim International Gmbh |
Monoclonal antibodies against human TNF-binding protein I (TNF-BP I) and immunoassays therefor
|
IL99120A0
(en)
*
|
1991-08-07 |
1992-07-15 |
Yeda Res & Dev |
Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
|
WO1993004375A1
(en)
*
|
1991-08-23 |
1993-03-04 |
Nchip, Inc. |
Burn-in technologies for unpackaged integrated circuits
|
ES2038546B1
(es)
*
|
1991-11-08 |
1994-02-16 |
Andromaco Lab |
Procedimiento de obtencion de un producto de naturaleza polipeptidica con actividad inhibidora de la hiperproduccion del factor de necrosis tumoral.
|
WO1995024501A1
(en)
|
1994-03-07 |
1995-09-14 |
Cetus Oncology Corporation |
Compositions for the inhibition of tnf formation and uses thereof
|
US5847099A
(en)
*
|
1994-10-19 |
1998-12-08 |
Genetics Institute, Inc. |
TNF receptor death domain ligand proteins
|
US5849501A
(en)
*
|
1994-10-19 |
1998-12-15 |
Genetics Institute, Inc. |
TNF receptor death domain ligand proteins and method to identify inhibitors of ligand binding
|
US5852173A
(en)
*
|
1994-10-19 |
1998-12-22 |
Genetics Institute, Inc. |
TNF receptor death ligand proteins and inhibitors of ligand binding
|
US5712381A
(en)
*
|
1994-10-19 |
1998-01-27 |
Genetics Institute, Inc. |
MADD, a TNF receptor death domain ligand protein
|
IL114615A0
(en)
|
1995-07-16 |
1995-11-27 |
Yeda Res & Dev |
Modulators of the function of fas receptors and other proteins
|
KR100368684B1
(ko)
*
|
1994-12-21 |
2003-03-19 |
주식회사 엘지생명과학 |
세포막에존재하는수용체의특정세포질내도메인을이용하여해당수용체의신호전달을차단하는방법
|
US7012060B1
(en)
*
|
1995-07-14 |
2006-03-14 |
Applied Research Systems Ars Holding N.V. |
TNF receptor and steroid hormone in a combined therapy
|
DE19724546C2
(de)
*
|
1996-06-14 |
1999-12-02 |
Uwe Hobohm |
Pharmazeutische Zusammensetzung zur Behandlung von Krebs sowie Kit zur Herstellung dieser Zusammensetzung
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
ES2207759T3
(es)
|
1996-12-06 |
2004-06-01 |
Amgen Inc. |
Terapia de combinacion que utiliza una proteina de union del factor de necrosis tumoral (tnf) en el tratamiento de enfermedades inducidas por el tnf.
|
WO1998024477A1
(en)
|
1996-12-06 |
1998-06-11 |
Amgen Inc. |
Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
|
US6473790B1
(en)
*
|
1997-02-07 |
2002-10-29 |
Casio Computer Co., Ltd. |
Network system for serving information to mobile terminal apparatus
|
US6346388B1
(en)
|
1997-08-13 |
2002-02-12 |
Smithkline Beecham Corporation |
Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2
|
US6297022B1
(en)
|
1997-10-08 |
2001-10-02 |
Smithkline Beecham Corporation |
Method of identifying agonists and antagonists for tumor necrosis related receptor TR1
|
US6893838B1
(en)
|
1998-04-07 |
2005-05-17 |
Genetics Institute Llc |
DADD, death activator death domain protein
|
US6197744B1
(en)
*
|
1998-09-21 |
2001-03-06 |
Health Research, Inc. |
Tumor necrosis factor inhibitory protein tip B1 and method of using same
|
US6660843B1
(en)
*
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
IL132105A0
(en)
*
|
1998-12-24 |
2001-03-19 |
Yeda Res & Dev |
Caspase-8 interacting proteins
|
US20040220103A1
(en)
|
1999-04-19 |
2004-11-04 |
Immunex Corporation |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
US6808902B1
(en)
|
1999-11-12 |
2004-10-26 |
Amgen Inc. |
Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
|
EP1237575B1
(de)
*
|
1999-12-14 |
2008-08-06 |
Genentech, Inc. |
Lfa-1 antagonisten und tnf-alpha antagonisten zur behandlung von rheumatoiden arthritis
|
US7101974B2
(en)
*
|
2000-03-02 |
2006-09-05 |
Xencor |
TNF-αvariants
|
US7662367B2
(en)
*
|
2000-03-02 |
2010-02-16 |
Xencor, Inc. |
Pharmaceutical compositions for the treatment of TNF-α related disorders
|
AU4541101A
(en)
|
2000-03-02 |
2001-09-12 |
Xencor Inc |
Design and discovery of protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
|
US20070172449A1
(en)
*
|
2000-03-02 |
2007-07-26 |
Xencor, Inc. |
TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS
|
US7446174B2
(en)
|
2001-03-02 |
2008-11-04 |
Xencor, Inc. |
Protein based TNF-α variants for the treatment of TNF-α related disorders
|
US7244823B2
(en)
*
|
2000-03-02 |
2007-07-17 |
Xencor |
TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
|
US7687461B2
(en)
*
|
2000-03-02 |
2010-03-30 |
Xencor, Inc. |
Treatment of TNF-α related disorders with TNF-α variant proteins
|
TWI322154B
(en)
|
2000-03-16 |
2010-03-21 |
Amgen Inc |
Il-17 receptor like molecules and uses thereof
|
DE10016877A1
(de)
|
2000-04-05 |
2001-10-18 |
Scintec Diagnostics Gmbh Zug |
(Glyko-)Proteine mit hoher Immunreaktivität sowie ein Verfahren zu ihrer Herstellung
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
DE10054279A1
(de)
*
|
2000-11-02 |
2002-05-16 |
Apotech Res & Dev Ltd |
Verwendung von Liganden von Todesrezeptoren oder RIP zur Auslösung des Caspase-unabhängigen Zelltods und Verbindungen zur Inhibition des Caspase-unabhängigen Zelltods
|
NZ547695A
(en)
|
2001-06-26 |
2008-09-26 |
Amgen Fremont Inc |
Antibodies to OPGL
|
TWI334439B
(en)
|
2001-08-01 |
2010-12-11 |
Centocor Inc |
Anti-tnf antibodies, compositions, methods and uses
|
US7084257B2
(en)
|
2001-10-05 |
2006-08-01 |
Amgen Inc. |
Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
|
CA2464529A1
(en)
*
|
2001-11-06 |
2003-05-15 |
Applied Research Systems Ars Holding N.V. |
Method of treating estrogen responsive breast cancer
|
IL161630A0
(en)
*
|
2001-11-06 |
2004-09-27 |
Applied Research Systems |
Methods of treating endometreosis
|
US20040002451A1
(en)
|
2002-06-20 |
2004-01-01 |
Bruce Kerwin |
Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
|
US9028822B2
(en)
|
2002-06-28 |
2015-05-12 |
Domantis Limited |
Antagonists against TNFR1 and methods of use therefor
|
JP2006517191A
(ja)
|
2002-12-30 |
2006-07-20 |
アムジエン・インコーポレーテツド |
共刺激因子を用いた併用療法
|
US7892563B2
(en)
|
2003-05-20 |
2011-02-22 |
Wyeth Holdings Corporation |
Methods for treatment of severe acute respiratory syndrome (SARS)
|
RU2007119989A
(ru)
*
|
2004-12-02 |
2009-01-10 |
Домантис Лимитед (Gb) |
Композиции, слитые конструкции и конъюгаты plad домена
|
EP1951872A2
(de)
*
|
2005-11-10 |
2008-08-06 |
The University of North Carolina at Chapel Hill |
Spleisswechsel-oligomere für tnf-superfamilie-rezeptoren und deren verwendung bei der behandlung von krankheiten
|
US7785834B2
(en)
*
|
2005-11-10 |
2010-08-31 |
Ercole Biotech, Inc. |
Soluble TNF receptors and their use in treatment of disease
|
US8007790B2
(en)
|
2006-04-03 |
2011-08-30 |
Stowers Institute For Medical Research |
Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
|
US7767206B2
(en)
|
2006-10-02 |
2010-08-03 |
Amgen Inc. |
Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
|
US20090264353A1
(en)
*
|
2007-10-19 |
2009-10-22 |
Santaris Pharma A/S |
Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
|
US20090182035A1
(en)
*
|
2007-04-11 |
2009-07-16 |
Alcon Research, Ltd. |
Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
|
WO2008127975A2
(en)
*
|
2007-04-11 |
2008-10-23 |
Alcon Research, Ltd. |
Use of an inhibitor of tnfa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
|
US8415291B2
(en)
|
2008-10-31 |
2013-04-09 |
Centocor Ortho Biotech Inc. |
Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
|
WO2011041640A1
(en)
*
|
2009-10-01 |
2011-04-07 |
Alcon Research, Ltd. |
Olopatadine compositions and uses thereof
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
ES2652637T3
(es)
|
2010-01-15 |
2018-02-05 |
Kirin-Amgen, Inc. |
Formulación de anticuerpos y regímenes terapéuticos
|
US20140234330A1
(en)
|
2011-07-22 |
2014-08-21 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
KR102530900B1
(ko)
|
2014-03-31 |
2023-05-12 |
암젠 케이-에이, 인크. |
손발톱 및 두피 건선의 치료 방법
|
US10465003B2
(en)
|
2016-02-05 |
2019-11-05 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
|
JP2020506916A
(ja)
|
2017-01-30 |
2020-03-05 |
ヤンセン バイオテツク,インコーポレーテツド |
活動性乾癬性関節炎の治療のための抗tnf抗体、組成物、及び方法
|
CA3052578A1
(en)
|
2017-02-07 |
2018-08-16 |
Janssen Biotech, Inc. |
Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
|
JP2022534020A
(ja)
|
2019-05-23 |
2022-07-27 |
ヤンセン バイオテツク,インコーポレーテツド |
Il-23及びtnfアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
|